266 related articles for article (PubMed ID: 28033329)
1. Myoinositol as a Biomarker in Recurrent Glioblastoma Treated with Bevacizumab: A 1H-Magnetic Resonance Spectroscopy Study.
Steidl E; Pilatus U; Hattingen E; Steinbach JP; Zanella F; Ronellenfitsch MW; Bähr O
PLoS One; 2016; 11(12):e0168113. PubMed ID: 28033329
[TBL] [Abstract][Full Text] [Related]
2. Myo-Inositol Levels Measured with MR Spectroscopy Can Help Predict Failure of Antiangiogenic Treatment in Recurrent Glioblastoma.
El-Abtah ME; Wenke MR; Talati P; Fu M; Kim D; Weerasekera A; He J; Vaynrub A; Vangel M; Rapalino O; Andronesi O; Arrillaga-Romany I; Forst DA; Yen YF; Rosen B; Batchelor TT; Gonzalez RG; Dietrich J; Gerstner ER; Ratai EM
Radiology; 2022 Feb; 302(2):410-418. PubMed ID: 34751617
[TBL] [Abstract][Full Text] [Related]
3. Leakage decrease detected by dynamic susceptibility-weighted contrast-enhanced perfusion MRI predicts survival in recurrent glioblastoma treated with bevacizumab.
Hilario A; Sepulveda JM; Hernandez-Lain A; Salvador E; Koren L; Manneh R; Ruano Y; Perez-Nuñez A; Lagares A; Ramos A
Clin Transl Oncol; 2017 Jan; 19(1):51-57. PubMed ID: 27026567
[TBL] [Abstract][Full Text] [Related]
4. A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma.
Weathers SP; Han X; Liu DD; Conrad CA; Gilbert MR; Loghin ME; O'Brien BJ; Penas-Prado M; Puduvalli VK; Tremont-Lukats I; Colen RR; Yung WKA; de Groot JF
J Neurooncol; 2016 Sep; 129(3):487-494. PubMed ID: 27406589
[TBL] [Abstract][Full Text] [Related]
5. Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma.
Kickingereder P; Wiestler B; Burth S; Wick A; Nowosielski M; Heiland S; Schlemmer HP; Wick W; Bendszus M; Radbruch A
Neuro Oncol; 2015 Aug; 17(8):1139-47. PubMed ID: 25754089
[TBL] [Abstract][Full Text] [Related]
6. Noninvasive Characterization of Tumor Angiogenesis and Oxygenation in Bevacizumab-treated Recurrent Glioblastoma by Using Dynamic Susceptibility MRI: Secondary Analysis of the European Organization for Research and Treatment of Cancer 26101 Trial.
Kickingereder P; Brugnara G; Hansen MB; Nowosielski M; Pflüger I; Schell M; Isensee F; Foltyn M; Neuberger U; Kessler T; Sahm F; Wick A; Heiland S; Weller M; Platten M; von Deimling A; Maier-Hein KH; Østergaard L; van den Bent MJ; Gorlia T; Wick W; Bendszus M
Radiology; 2020 Oct; 297(1):164-175. PubMed ID: 32720870
[TBL] [Abstract][Full Text] [Related]
7. Intracellular pH measured by
Wenger KJ; Hattingen E; Franz K; Steinbach JP; Bähr O; Pilatus U
J Magn Reson Imaging; 2017 Oct; 46(4):1200-1208. PubMed ID: 28165649
[TBL] [Abstract][Full Text] [Related]
8. Multimodal imaging patterns predict survival in recurrent glioblastoma patients treated with bevacizumab.
Chang K; Zhang B; Guo X; Zong M; Rahman R; Sanchez D; Winder N; Reardon DA; Zhao B; Wen PY; Huang RY
Neuro Oncol; 2016 Dec; 18(12):1680-1687. PubMed ID: 27257279
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial.
Beije N; Kraan J; Taal W; van der Holt B; Oosterkamp HM; Walenkamp AM; Beerepoot L; Hanse M; van Linde ME; Otten A; Vernhout RM; de Vos FY; Gratama JW; Sleijfer S; van den Bent MJ
Br J Cancer; 2015 Jul; 113(2):226-31. PubMed ID: 26042933
[TBL] [Abstract][Full Text] [Related]
10. Recurrent glioblastoma: volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab.
Huang RY; Rahman R; Hamdan A; Kane C; Chen C; Norden AD; Reardon DA; Mukundun S; Wen PY
Cancer; 2013 Oct; 119(19):3479-88. PubMed ID: 23821555
[TBL] [Abstract][Full Text] [Related]
11. Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial.
Schmainda KM; Zhang Z; Prah M; Snyder BS; Gilbert MR; Sorensen AG; Barboriak DP; Boxerman JL
Neuro Oncol; 2015 Aug; 17(8):1148-56. PubMed ID: 25646027
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab impairs oxidative energy metabolism and shows antitumoral effects in recurrent glioblastomas: a 31P/1H MRSI and quantitative magnetic resonance imaging study.
Hattingen E; Jurcoane A; Bähr O; Rieger J; Magerkurth J; Anti S; Steinbach JP; Pilatus U
Neuro Oncol; 2011 Dec; 13(12):1349-63. PubMed ID: 21890539
[TBL] [Abstract][Full Text] [Related]
13. VEGF-121 plasma level as biomarker for response to anti-angiogenetic therapy in recurrent glioblastoma.
Martini M; de Pascalis I; D'Alessandris QG; Fiorentino V; Pierconti F; Marei HE; Ricci-Vitiani L; Pallini R; Larocca LM
BMC Cancer; 2018 May; 18(1):553. PubMed ID: 29747600
[TBL] [Abstract][Full Text] [Related]
14. Pretreatment ADC histogram analysis is a predictive imaging biomarker for bevacizumab treatment but not chemotherapy in recurrent glioblastoma.
Ellingson BM; Sahebjam S; Kim HJ; Pope WB; Harris RJ; Woodworth DC; Lai A; Nghiemphu PL; Mason WP; Cloughesy TF
AJNR Am J Neuroradiol; 2014 Apr; 35(4):673-9. PubMed ID: 24136647
[TBL] [Abstract][Full Text] [Related]
15. Large-volume low apparent diffusion coefficient lesions predict poor survival in bevacizumab-treated glioblastoma patients.
Zhang M; Gulotta B; Thomas A; Kaley T; Karimi S; Gavrilovic I; Woo KM; Zhang Z; Arevalo-Perez J; Holodny AI; Rosenblum M; Young RJ
Neuro Oncol; 2016 May; 18(5):735-43. PubMed ID: 26538618
[TBL] [Abstract][Full Text] [Related]
16. Toxicity and efficacy of lomustine and bevacizumab in recurrent glioblastoma patients.
Jakobsen JN; Urup T; Grunnet K; Toft A; Johansen MD; Poulsen SH; Christensen IJ; Muhic A; Poulsen HS
J Neurooncol; 2018 Apr; 137(2):439-446. PubMed ID: 29330749
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab-induced hypertension is a predictive marker for improved outcomes in patients with recurrent glioblastoma treated with bevacizumab.
Zhong J; Ali AN; Voloschin AD; Liu Y; Curran WJ; Crocker IR; Shu HK
Cancer; 2015 May; 121(9):1456-62. PubMed ID: 25557543
[TBL] [Abstract][Full Text] [Related]
18. The role of early magnetic resonance imaging in predicting survival on bevacizumab for recurrent glioblastoma: Results from a prospective clinical trial (CABARET).
Field KM; Phal PM; Fitt G; Goh C; Nowak AK; Rosenthal MA; Simes J; Barnes EH; Sawkins K; Cher LM; Hovey EJ; Wheeler H
Cancer; 2017 Sep; 123(18):3576-3582. PubMed ID: 28678383
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma.
Lee EQ; Reardon DA; Schiff D; Drappatz J; Muzikansky A; Grimm SA; Norden AD; Nayak L; Beroukhim R; Rinne ML; Chi AS; Batchelor TT; Hempfling K; McCluskey C; Smith KH; Gaffey SC; Wrigley B; Ligon KL; Raizer JJ; Wen PY
Neuro Oncol; 2015 Jun; 17(6):862-7. PubMed ID: 25572329
[TBL] [Abstract][Full Text] [Related]
20. Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio.
Chinot OL; Nishikawa R; Mason W; Henriksson R; Saran F; Cloughesy T; Garcia J; Revil C; Abrey L; Wick W
Neuro Oncol; 2016 Sep; 18(9):1313-8. PubMed ID: 27006178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]